Literature DB >> 27220761

UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.

Chunlei Xu1, Xushan Tang1, Yanli Qu1, Saifuding Keyoumu1, Ning Zhou1, Yong Tang2.   

Abstract

OBJECTIVES: To investigate the relationship between uridine diphosphate glucoronosyltransferase 1A1 (UGT1A1)*28/*6 and toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer (CRC) in Xinjiang Uygur and Han population.
METHODS: A total of 183 patients (Uygur, 114; Han, 69) with advanced CRC who received the irinotecan-based chemotherapy were enrolled in this retrospective analysis. Polymerase chain reaction amplification and direct sequencing method were used for UGT1A1*28 and UGT1A1*6 polymorphism detection. The patients were followed up to analyze the relationship between different genotypes with adverse reactions and the clinical outcome of irinotecan-based chemotherapy.
RESULTS: Significant differences were found in genotype frequencies of UGT1A1*28 and UGT1A1*28/*6 between Uygur and Han (P = 0.02 and P = 0.002). Uygur and Han patients carrying wild UGT1A1*28 and *6 genotypes appeared to have significantly lower diarrhea incidence (I/II and III/IV) than those carrying mutant genotypes (all P < 0.05). In Uygur patients, UGT1A1*28 genotypes were related with objective response rate and disease control rate (P < 0.05). Compared with *1 allele *1/*1, *1 allele *1/*28*1/*28 mutant of UGT1A1*28 was associated with shorter OS in both Uygur and Han ethnicities (all P < 0.05). Compared with double allele variants (DW), single allele variants (SV), and double allele variants (DV) of UGT1A1*28/*6 were associated with shorter overall survival (OS) in Uygur and Han (all P < 0.05). Cox regression analysis revealed factors significantly influencing OS, including UGT1A1*28, UGT1A1*6, combined genotypes and chemotherapy line in Ugyur, and only combined genotypes in Han (all P < 0.05).
CONCLUSION: UGT1A1 gene polymorphism predicts irinotecan-related adverse reactions in advanced CRC patients of Xinjiang Uygur and Han nationality; UGT1A1 gene polymorphism is correlated with efficacy and prognosis in Uygur nationality, but only related to prognosis in Han nationality in irinotecan-based chemotherapy.

Entities:  

Keywords:  Advanced colorectal cancer; Clinical efficacy; Han nationality; Irinotecan-based chemotherapy; Polymorphism; Toxicity; UGT1A1; Uygur nationality

Mesh:

Substances:

Year:  2016        PMID: 27220761     DOI: 10.1007/s00280-016-3057-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

Review 1.  Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

2.  The prognostic impact of serum bilirubin in stage IV colorectal cancer patients.

Authors:  Lin Yang; Lu-Yao Ge; Ting Yu; Yan Liang; Ying Yin; Hong Chen
Journal:  J Clin Lab Anal       Date:  2017-11-23       Impact factor: 2.352

3.  Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria.

Authors:  Maristela P Freire; Ligia C Pierrotti; Antonio E Zerati; Luciana Benites; Joaquim Mauricio da Motta-Leal Filho; Karim Y Ibrahim; Pedro H Araujo; Edson Abdala
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Gilbert's Syndrome, Bilirubin Level and UGT1A1∗28 Genotype in Men of North-West Region of Russia.

Authors:  Andrei Ivanov; Elena Semenova
Journal:  J Clin Exp Hepatol       Date:  2021-02-04

5.  Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.

Authors:  Chalirmporn Atasilp; Mohitosh Biswas; Pimonpan Jinda; Nutthan Nuntharadthanaphong; Jiratha Rachanakul; Yaowaluck Hongkaew; Natchaya Vanwong; Surasak Saokaew; Chonlaphat Sukasem
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

6.  Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.

Authors:  Yu Bai; Hai-Wei Wu; Xu Ma; Ying Liu; Yan-Hua Zhang
Journal:  Onco Targets Ther       Date:  2017-06-19       Impact factor: 4.147

7.  Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.

Authors:  Dan Liu; Jian Li; Jing Gao; Yanyan Li; Rui Yang; Lin Shen
Journal:  BMC Cancer       Date:  2017-06-20       Impact factor: 4.430

8.  UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study.

Authors:  Marcelo Moreira Tavares de Souza; Victor Van Vaisberg; Rodrigo Martins Abreu; Aline Siqueira Ferreira; Camila daSilvaFerreira; Paulo Dominguez Nasser; Helena Scavone Paschoale; Flair José Carrilho; Suzane Kioko Ono
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

9.  Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.

Authors:  Xing-Han Liu; Jun Lu; Wei Duan; Zhi-Ming Dai; Meng Wang; Shuai Lin; Peng-Tao Yang; Tian Tian; Kang Liu; Yu-Yao Zhu; Yi Zheng; Qian-Wen Sheng; Zhi-Jun Dai
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

10.  [Detection of UGT1A1*28 Polymorphism Using Fragment Analysis].

Authors:  Ying Huang; Jian Su; Xiaosui Huang; Danxia Lu; Zhi Xie; Suqing Yang; Weibang Guo; Zhiyi Lv; Hongsui Wu; Xuchao Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.